
## Amendments to the claims:

## 1-64 (cancelled)

- 65. (currently amended) A pharmaceutical composition comprising a monovalent antibody fragment which prevents the binding of von Willebrand factor (vWF) to human platelet glycoprotein Ib (GPIb) and binds *in vivo* to human platelet glycoprotein GPIb without incurring thrombocytopenia and a pharmaceutically acceptable carrier.
- 66. (previously presented) The pharmaceutical composition according to claim 65, wherein said fragment is a Fab fragment or a single variable domain.
- 67. (cancelled)
- 68. (cancelled)
- 69. (cancelled)
- 70. (previously presented) The pharmaceutical composition according to claim 65, wherein the variable region of said fragment comprises SEQ ID NO: 4.
- 71. (previously presented) The pharmaceutical composition according to claim 65, wherein said monovalent antibody fragment is obtained from a monoclonal antibody produced by the cell line deposited with the Belgian Coordinated Collections of Microorganisms, under accession number LMBP 5108CB.

## 72. (cancelled)



84. (new) A monovalent antibody fragment which binds *in vivo* to human platelet GPIb and prevents the binding of von Willebrand factor to human platelet GPIb, wherein said monovalent antibody fragment is obtained from a monoclonal antibody produced by the cell line deposited with the Belgian Coordinated Collections of Microorganisms under accession number LMBP 5108CB.

85. (new) A monovalent antibody fragment which binds *in vivo* to human platelet GPIb and prevents the binding of von Willebrand factor to human platelet GPIb, wherein said monovalent antibody fragment includes a variable region comprising SEQ ID NO:4.